PAA 2.63% 19.5¢ pharmaust limited

Ann: MND Trial Successfully Completes First Patient Cohort, page-156

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,855 Posts.
    lightbulb Created with Sketch. 2902
    mTor pathway common in multiple Neuro degenerative diseases. Monepatel is a potent mTor inhibitor so MND is proof of concept but can have much broader utility and thus value!

    https://hotcopper.com.au/data/attachments/5933/5933193-4c972d59074a330e53b1b14d2a05936b.jpg

    https://hotcopper.com.au/data/attachments/5933/5933223-c0f6ea5d9d86d704c98f6a69ad1b945d.jpghttps://hotcopper.com.au/data/attachments/5933/5933198-729e9063b7239203a48b19cffec0505e.jpg

    Monepatel mTor inhibitor MOA
    https://hotcopper.com.au/data/attachments/5933/5933225-2e2cb56f6417cafcbdc84da725aad95e.jpg

    https://hotcopper.com.au/data/attachments/5933/5933229-fd35c2254688b208699a32c957434a4f.jpg
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.